Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention. - Suppr | 超能文献

Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention.

作者信息

Kawada Tomoyuki

机构信息

Department of Hygiene and Public Health, Nippon Medical School, Japan.

出版信息

Clin Biochem. 2017 Dec;50(18):1326-1327. doi: 10.1016/j.clinbiochem.2017.07.015. Epub 2017 Jul 25.

DOI:10.1016/j.clinbiochem.2017.07.015

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention.

Clin Biochem. 2017 Dec;50(18):1326-1327. doi: 10.1016/j.clinbiochem.2017.07.015. Epub 2017 Jul 25.

2

Response to the letter to the editor: Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention.致编辑的信的回复：冠状动脉疾病和经皮冠状动脉介入治疗患者碱性磷酸酶升高的死亡风险

Clin Biochem. 2017 Dec;50(18):1328-1329. doi: 10.1016/j.clinbiochem.2017.07.014. Epub 2017 Jul 25.

3

Percutaneous coronary intervention compared with coronary artery bypass graft in coronary artery disease patients with chronic kidney disease: a systematic review and meta-analysis.慢性肾脏病冠心病患者经皮冠状动脉介入治疗与冠状动脉旁路移植术的比较：一项系统评价和荟萃分析。

Ren Fail. 2014 Sep;36(8):1177-86. doi: 10.3109/0886022X.2014.934178. Epub 2014 Jul 2.

4

Optimal Treatment Strategies in Patients with Chronic Kidney Disease and Coronary Artery Disease.慢性肾脏病和冠状动脉疾病患者的最佳治疗策略。

Am J Med. 2016 Dec;129(12):1288-1298. doi: 10.1016/j.amjmed.2016.06.046. Epub 2016 Jul 28.

5

Coronary artery surgery versus percutaneous coronary intervention in octogenarians: long-term results.老年患者冠状动脉搭桥手术与经皮冠状动脉介入治疗的长期结果比较

Ann Thorac Surg. 2015 Feb;99(2):567-74. doi: 10.1016/j.athoracsur.2014.09.019. Epub 2014 Dec 10.

6

Increased mortality and perioperative complications in patients with previous elective percutaneous coronary interventions undergoing coronary artery bypass surgery.既往接受择期经皮冠状动脉介入治疗的患者在接受冠状动脉旁路移植术时死亡率和围手术期并发症增加。

J Thorac Cardiovasc Surg. 2009 Apr;137(4):846-52. doi: 10.1016/j.jtcvs.2008.09.041.

7

Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease: An External Validation of the SYNTAX Score II Model in the 1,480 Patients of the BEST and PRECOMBAT Randomized Controlled Trials.多支血管病变和/或无保护左主干病变患者行冠状动脉支架置入术或旁路移植术的个体长期死亡率预测：SYNTAX II 评分模型在 BEST 和 PRECOMBAT 随机对照试验 1480 例患者中的外部验证。

JACC Cardiovasc Interv. 2016 Aug 8;9(15):1564-72. doi: 10.1016/j.jcin.2016.04.023.

8

Narrowing the gap: early and intermediate outcomes after percutaneous coronary intervention and coronary artery bypass graft procedures in California, 1997 to 2006.缩小差距：1997年至2006年加利福尼亚州经皮冠状动脉介入治疗和冠状动脉旁路移植手术后的早期及中期结果

J Thorac Cardiovasc Surg. 2009 Nov;138(5):1100-7. doi: 10.1016/j.jtcvs.2009.03.069.

9

Long-term follow-up of a randomized, controlled clinical trial of three therapeutic strategies for multivessel stable coronary artery disease in women.一项针对女性多支血管稳定型冠状动脉疾病三种治疗策略的随机对照临床试验的长期随访

Interact Cardiovasc Thorac Surg. 2014 Dec;19(6):997-1001. doi: 10.1093/icvts/ivu288. Epub 2014 Sep 2.

10

Alkaline phosphatase and prognosis in patients with coronary artery disease.碱性磷酸酶与冠心病患者的预后

Eur J Clin Invest. 2017 May;47(5):378-387. doi: 10.1111/eci.12752. Epub 2017 Apr 25.

引用本文的文献

1

A retrospective cross-sectional study for predicting 72-h mortality in patients with serum aspartate aminotransferase levels ≥ 3000 U/L.一项回顾性横断面研究，旨在预测血清天冬氨酸氨基转移酶水平≥3000 U/L 的患者 72 小时死亡率。

Sci Rep. 2021 Jan 12;11(1):800. doi: 10.1038/s41598-020-79435-3.